Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices

Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses....

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-09, Vol.10 (10), p.1619
Main Authors: Geiger, Nina, König, Eva-Maria, Oberwinkler, Heike, Roll, Valeria, Diesendorf, Viktoria, Fähr, Sofie, Obernolte, Helena, Sewald, Katherina, Wronski, Sabine, Steinke, Maria, Bodem, Jochen
Format: Article
Language:English
Subjects:
Acetylsalicylic acid
Acids
Antiviral activity
Aspirin
Cell culture
Cell growth
Communication
COVID-19
Cytotoxicity
Dosage and administration
Drugs
Evaluation
Experiments
Gene expression
Genomes
Health aspects
Infections
Influenza
Lungs
Metabolites
Orthomyxoviridae
Pandemics
Patients
precision-cut lung slices
Process controls
Replication
RNA polymerase
Salicylic acid
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Viral infections
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10101619